Joe Rogan TRT: How His Protocol Compares to Similar Public Figures

What Has Joe Rogan Actually Said About TRT?

Rogan has been unusually candid about testosterone replacement therapy for a public figure of his reach. Across multiple episodes of the Joe Rogan Experience, he has described using TRT to address the natural testosterone decline that accompanies aging, stating explicitly that his levels were low enough that he felt it warranted medical intervention. He has not, to date, published lab values or dose specifics.

His Own Words

In a widely clipped 2020 episode, Rogan told guest Andrew Huberman: "I'm on TRT. I've been on it for a while. My testosterone was low, I got it checked, and my doctor put me on it." That statement is a primary disclosure. No dose or ester was named in that segment.

On a separate episode with physician Mark Gordon, Rogan discussed the broader philosophy of hormone optimization in aging men, describing TRT as corrective rather than performance-enhancing in his case. This framing is consistent with how clinical guidelines distinguish therapeutic TRT from supraphysiologic androgen use.

What "Low Testosterone" Means Clinically

The American Urological Association defines hypogonadism as a morning total testosterone level below 300 ng/dL on two separate measurements, accompanied by symptoms. [1] Symptoms in men over 50 commonly include fatigue, reduced libido, decreased lean mass, and mood changes. [2]

Rogan has referenced all of those symptom categories on air, though he has not linked them directly to a specific lab number. The clinical threshold of 300 ng/dL is the reference point his physician would have used.

NAD+ and Peptides: The Rest of the Stack

Beyond testosterone, Rogan has discussed NAD+ intravenous infusions repeatedly. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in mitochondrial energy metabolism, and preclinical data suggest it declines with age. [3] Human clinical data are still limited: a 2023 randomized trial (N=30) published in Nature Aging found that NMN supplementation raised blood NAD+ levels but did not produce statistically significant changes in primary fatigue endpoints. [4]

He has also mentioned BPC-157, a synthetic peptide derived from a gastric protein sequence, citing joint recovery and gut health. BPC-157 has preclinical support in rodent models but lacks FDA approval and has no completed Phase II or III human trials as of mid-2025. [5] Rogan has typically noted that peptide use requires a compounding pharmacy prescription in the United States.

The Clinical Picture: Is Rogan's Protocol Normal for His Age Group?

A 57-year-old man with documented low testosterone is squarely within the population for whom TRT is evidence-supported. The American Urological Association 2024 guideline states: "Clinicians should offer testosterone therapy to men with symptomatic hypogonadism after confirming the diagnosis biochemically." [1]

Testosterone Decline by Decade

Total testosterone in men declines at approximately 1.0 to 1.6 percent per year after age 30. [6] By age 57, a man who started at 700 ng/dL at age 30 could be sitting at roughly 330 to 420 ng/dL without treatment, placing him close to or below the clinical threshold depending on baseline.

A 2017 study in the Journal of Clinical Endocrinology and Metabolism (N=9,054) found the prevalence of biochemical hypogonadism (total T < 300 ng/dL) to be approximately 20 percent in men aged 60 to 69. [7] Rogan's demographic is not unusual.

Standard TRT Formulations

Physicians prescribing TRT for hypogonadism typically use one of three formulations:

• Testosterone cypionate or enanthate injected intramuscularly every 7 to 14 days, typically 100 to 200 mg per injection
• Topical testosterone gel (AndroGel, Testim), applied daily at 1.62 percent concentration
• Testosterone pellets (Testopel) implanted subcutaneously every 3 to 6 months

Rogan has referenced injections specifically in at least one episode, though he has not specified the ester or dose. Testosterone cypionate is the most commonly prescribed injectable form in the United States. [8]

Monitoring Requirements

The Endocrine Society's 2018 Clinical Practice Guideline recommends checking hematocrit, PSA, and testosterone levels at 3 to 6 months after initiating therapy, then annually. [9] Elevated hematocrit (above 54 percent) is the most common adverse effect requiring dose adjustment or temporary discontinuation.

Comparing Rogan to Similar Male Public Figures

Several other public figures in the 45 to 65 age bracket have disclosed hormone or longevity protocols with varying degrees of specificity. The comparison below is grounded in their own public statements only. Where details are inferred, that is labeled.

Bryan Johnson (Age 47, Entrepreneur, Blueprint Protocol)

Bryan Johnson is the most data-transparent figure in this space. He publishes monthly bloodwork, protocol documents, and outcome metrics on his website and through peer-reviewed preprints. His testosterone protocol, as disclosed in 2023 documentation, targets a morning total testosterone of 800 to 1,000 ng/dL using a low-dose injectable regimen combined with HCG (human chorionic gonadotropin) to preserve testicular function. He has also publicly disclosed growth hormone secretagogue use (ipamorelin/CJC-1295).

The key difference from Rogan: Johnson aims for optimized supraphysiologic range, not merely corrective replacement. Rogan's stated framing is symptom relief and restoration to normal range, a clinically meaningful distinction.

Andrew Huberman (Age 49, Neuroscientist, Stanford)

Huberman has discussed testosterone on his podcast at length without confirming personal TRT use. He has disclosed taking tongkat ali (eurycoma longifolia), a botanical that modestly raises endogenous testosterone in men with low-normal levels. A 2022 randomized trial (N=105) found tongkat ali 400 mg/day raised total testosterone by a mean of 122 ng/dL over 12 weeks in men with testosterone below 400 ng/dL. [10] That is a real but modest effect compared to pharmaceutical TRT.

Huberman occupies a distinct category: documented botanical supplementation rather than pharmaceutical hormone replacement.

Ben Greenfield (Age 43, Fitness Author)

Greenfield has disclosed testosterone cream use, peptide stacks including BPC-157 and TB-500, and growth hormone secretagogues in multiple podcast interviews and his book "Boundless." His disclosures are among the most granular of any public figure in this niche. He has also discussed HCG use for testicular preservation while on exogenous testosterone, a protocol endorsed by some urologists for men who want to maintain fertility potential during TRT. [11]

Greenfield's protocol is arguably more aggressive than Rogan's based on public statements, though both share the use of peptides that remain outside FDA-approved indication.

Bob Harper (Age 58, Fitness Personality)

Harper has not publicly confirmed TRT use. He represents a control case in this comparison: a male fitness public figure in the same age range who, to public knowledge, has not disclosed hormone therapy. His protocol appears focused on cardiovascular rehabilitation following a 2017 heart attack.

The table below summarizes public disclosures. All entries are based solely on the individual's own public statements. Absence of disclosure does not mean absence of therapy.

| Public Figure | Age | TRT Disclosed | Peptides Disclosed | Transparency Level | |---|---|---|---|---| | Joe Rogan | 57 | Yes (self-report, no labs) | BPC-157, others | Moderate | | Bryan Johnson | 47 | Yes (labs published) | Yes (detailed) | High | | Andrew Huberman | 49 | No pharmaceutical TRT confirmed | No | Low | | Ben Greenfield | 43 | Yes (cream, self-report) | Yes (detailed) | High | | Bob Harper | 58 | No | No | N/A |

The Medical Legitimacy Question: Is This Medicine or Optimization?

This distinction matters clinically and legally. The FDA approved testosterone replacement for hypogonadism, not for age-related decline in men with testosterone in the normal range. Prescribing TRT to a eugonadal man (normal testosterone, no symptoms) is off-label. [12]

When TRT Is Guideline-Supported

The Endocrine Society's 2018 guideline is clear: "We recommend against making a diagnosis of hypogonadism in men with normal testosterone levels who have nonspecific symptoms." [9] Rogan's framing of documented low levels plus symptoms places him within the guideline-supported indication, assuming his self-report is accurate.

The guideline also notes: "The evidence base for long-term benefits and risks of testosterone therapy in older men is limited." The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, found that testosterone replacement in men aged 45 to 80 with hypogonadism and cardiovascular risk factors did not significantly increase major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months. [13] That trial provided meaningful safety data that had been lacking for decades.

When the Evidence Thins

BPC-157 and similar peptides occupy a grayer zone. The FDA issued a notice in 2023 classifying BPC-157 as a substance that raises significant safety concerns, prohibiting compounding pharmacies from including it in preparations under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. [14] Rogan's references to peptide use predate that ruling, and he has since acknowledged the regulatory field had shifted.

NAD+ infusions are not FDA-regulated as drugs when administered by licensed practitioners as IV nutrient therapy, but the evidence for systemic benefit in healthy humans remains thin. A 2020 review in Cell Metabolism concluded that oral NAD+ precursors raise plasma NAD+ levels reliably but that translating that to measurable human healthspan outcomes requires longer trials. [15]

Why This Discussion Reaches Millions

Rogan's podcast averages over 14 million listeners per episode, according to Edison Research estimates cited in a 2023 Reuters report. His open discussion of TRT has almost certainly increased demand for testosterone evaluations at men's health clinics. A 2020 analysis in JAMA Internal Medicine found a 29 percent increase in testosterone prescriptions between 2009 and 2013 that was partly attributed to direct-to-consumer media influence. [16]

The Normalization Effect

There is real clinical value in reducing stigma around hypogonadism. Many men avoid discussing fatigue, low libido, and mood changes with their physicians because they perceive those as signs of weakness. Rogan addressing this on air reaches the exact demographic (men in their 40s and 50s) most likely to have undiagnosed hypogonadism and least likely to seek care.

The Risk of Oversimplification

The risk, which clinicians consistently flag, is that public figures discussing protocols without disclosing full context (labs, symptoms, monitoring, physician oversight) can lead listeners to self-diagnose or pursue TRT without proper evaluation. The FDA requires a prescription for testosterone, and diagnosis requires two morning fasting blood draws, not a podcast recommendation.

A 2021 survey published in the Journal of Sexual Medicine (N=2,411 men) found that 24 percent of men who had purchased testosterone online had never had their testosterone levels measured. [17] That is the downstream cost of incomplete public communication about the therapy.

What a Physician Would Ask Before Replicating Rogan's Protocol

Any physician evaluating a patient who says "I want what Joe Rogan is on" would start with a structured workup, not a prescription pad.

Standard Pre-TRT Workup

• Two fasting morning total testosterone measurements (before 10 a.m.)
• LH and FSH to distinguish primary from secondary hypogonadism
• Complete blood count (baseline hematocrit)
• Comprehensive metabolic panel
• PSA (men over 40)
• Estradiol, SHBG, free testosterone (calculated or direct)
• DRE or urology referral for men over 50 with elevated PSA

A confirmed total testosterone below 300 ng/dL with symptoms meets the AUA threshold for initiating treatment. [1] A result between 300 and 400 ng/dL with symptoms enters a shared-decision-making zone.

What Rogan's Scenario Likely Looks Like Clinically

Based on his stated age, activity level, and symptom history (as disclosed on air), a clinician would classify him as a candidate for TRT under guideline criteria if his labs confirmed the diagnosis. The specific formulation, cypionate versus pellet versus gel, would depend on lifestyle factors and patient preference. Monitoring every 6 months is standard practice.

FAQs